MedPath

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: JR-131
Registration Number
NCT02912533
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Brief Summary

The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients being treated with erythropoiesis stimulating agent.
Read More
Exclusion Criteria
  • Patients having complication or history of a cardiovascular / lung / brain infarction.
  • Patients having a pronounced hemorrhagic lesion.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
JR-131JR-131-
Primary Outcome Measures
NameTimeMethod
Measure adverse events52 weeks
Secondary Outcome Measures
NameTimeMethod
Hemoglobin level52 weeks
© Copyright 2025. All Rights Reserved by MedPath